Pharma & biotech

Novo Nordisk partners with biotech accelerator in Switzerland

Since its founding in 2017, Baselaunch has backed 22 companies, ten of which have raised over USD 600m in total so far, while six companies have entered clinical development.
With Novo Nordisk as a partner, the Swiss biotech accelerator Baselaunch strengthens its global connections to the pharmaceutical industry, which in turn can boost the accelerator's activities in building biotech companies, according to an announcement. | Photo: Tom Little/Reuters/Ritzau Scanpix
With Novo Nordisk as a partner, the Swiss biotech accelerator Baselaunch strengthens its global connections to the pharmaceutical industry, which in turn can boost the accelerator's activities in building biotech companies, according to an announcement. | Photo: Tom Little/Reuters/Ritzau Scanpix
by ALBERT RØNNING-ANDERSSON

Novo Nordisk joins the ranks of large companies working with Swiss biotech accelerator Baselaunch, according to a statement from the Basel-based company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs